checkAd
    Startseite > Nachrichten > Analysen > Nachricht

     101  0 Kommentare Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers - Seite 3

    Contact:
    Stephen Stamp, CEO, CFO
    ir@biodexapharma.com

    Lesen Sie auch

    SOURCE: Biodexa Pharmaceuticals Plc



    View the original press release on accesswire.com


    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3
    Verfasst von Accesswire
    Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers - Seite 3 Topline Results For Progression-Free Survival Expected In Q2 2024CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ("Biodexa"), an acquisition-focused biopharmaceutical company, is developing MTX110 for the treatment …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer